Immunological control of β-amyloid levels in vivo
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 15, 2011
Grant Date -
Jul 7, 2005
app pub date -
Feb 23, 2005
filing date -
Jun 16, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a β-amyloid epitope. Also disclosed are methods for inhibiting the formation of β-amyloid plaques in the brain of a human, or promoting the disaggregation of a preformed β-amyloid plaque. Such methods recite the administration of a bispecific antibody.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully